

Freedom of Information Request

Ref: 23-347

1 June 2023

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

Q1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months?

Please note, the Trust does not hold the data in a format that would enable us to fully respond to your request to the level of detail required and a manual trawl for this information would significantly exceed the 18 hours limit set down by the FOI as the reasonable limit. Section 12 of the FOIA provides that we are not obliged to spend in excess of 18 hours in any sixty-day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

No, not applicable.

Q2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

- Paclitaxel in combination with a platinum-based compound 14
- Platinum-based therapy alone (cisplatin or carboplatin) 10
- Bevacizumab in combination with paclitaxel and carboplatin *
- Olaparib 7
- Olaparib + Bevacizumab 0
- Niraparib 8
- Rucaparib *

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The

Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Q3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Valtve1 trial – * patients

MONITOR – 13 patients

RaNGO – * patients (not solely ovarian cancer, includes other gynaecological cancers)

Athena trial – * patients in follow up

ICON8B – 24 patients in follow up

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:

- Olaparib 0
- Olaparib + Bevacizumab *
- Niraparib *
- Other treatments *

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Q5. If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with:

- Olaparib 0
- Olaparib + Bevacizumab 0
- Niraparib 0
- Other treatments 0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust